Received IND approval
from MFDS for Phase 1 clinical study for TXN10128

Completed IND submission
for clinical development of ENPP1 inhibitor, TXN10128

Signed the agreement of strategic investment
with Hyundai pharmaceuticals and started collaboration
for novel drug development.

Selected as a company receiving matching fund
from Korean venture investment

Closed first part of series B funding
(Korea investment Partners, Company K investment,
Solidus investment, Daily Partners,
Meditox venture investment)

Successfully completed Tech Incubator Program
for Startup korea grant

Launched a collaboration with HK inno.N
for novel drug development

Exchanged MOU with K-MEDIhub

Exchanged MOU with Ahngook Pharm.

Awarded Korea Drug Development Fund grant
for ENPP1 inhibitor

Awarded ministry of science
and information communication grant

Participated in the 2022 BIOUSA conference

Awarded bioresearch data generation support grant

Awarded AI voucher support grant for ULK1 inhibitor

Awarded Korea Drug Development Fund grant
for ULK1 inhibitor

Opened animal facility (named “spleen”)

Exchanged MOU with AnaPath for pre-clinical development

Participated in the 2021 BIO-EUROPE ®

Presented poster
at the 2021 AACR-NCI-EORTC annual conference

Exchanged MOU with HK Inno.N Corp.

Completed Series A funding round
(Korea Investment Partners, Schmidt,
DSC investment, Company K investment)

Closed 2^nd angel funding round

Opened headquarter and R&D center at Gwanggyo

Certified as a corporate affiliated research institute

Certified as a venture business corporation

Awarded Tech Incubator Program
for Startup Korea (TIPS) grant.

Completed Pre-A funding round
(Korea Investment Partners, Schmidt, DSC investment)

Closed 1^ST angel funding round

Launched Txinno Bioscience inc.

Started as Incubator Team #2 of BioStar project at KIST